Date: 2016-03-25
Type of information: Nomination
Compound:
Company: UCB (Belgium)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 25, 2016, UCB has published it convening notice and agenda for its Annual General Meeting which will take place on April 28, 2016. In the agenda, the Board of Directors of UCB SA is proposing to appoint Pierre Gurdjian and Ulf Wiinberg as new independent Directors at the company’s next General Assembly. Pending the approval by the next General Assembly, the new Board will include a majority of Independent Board members namely the following directors: Alice Dautry, Kay Davies, Albrecht De Graeve, Harriet Edelman, Norman J. Ornstein, Pierre Gurdjian and Ulf Wijnberg. Other members of the UCB Board of Directors are: Gerhard Mayr, Chairman, Evelyn du Monceau, Vice Chair, Jean-Christophe Tellier, Executive Director, Charles-Antoine Janssen, Cyril Janssen and Cédric van Rijckevorsel.
Pierre Gurdjian is currently Chairman of the Board of Directors of the Université Libre de Bruxelles and he teaches a graduate course in CEO Leadership at the Solvay Business School. He is also very active in the field of Philanthropy and Education. Previously he worked for nearly three decades at the management consultancy firm McKinsey & Company as a Senior Partner and, from 2005 to 2012, as head of the Belgian office.
Ulf Wiinberg is a seasoned healthcare industry professional. At Wyeth, he was President of the global consumer health care business, and later President for the European pharma business. Ulf was also CEO of Lundbeck for several years, a Nordic pharmaceutical company specialized in brain diseases. Ulf has served on the boards of several healthcare industry associations. He is today a non-executive Board member at Alfa Laval, a Swedish industrial company, and Nestle Health and Science; he is also Chairman of Avillion. At the next General Assembly on April 28, 2016, the mandates of Harriet Edelman and Charles-Antoine Janssen will be proposed for renewal. The mandate of Tom McKillop will come to an end and the former AstraZeneca's CEO will be stepping down.
Financial terms:
Latest news:
